Literature DB >> 27671644

SARM1-specific motifs in the TIR domain enable NAD+ loss and regulate injury-induced SARM1 activation.

Daniel W Summers1, Daniel A Gibson2, Aaron DiAntonio3, Jeffrey Milbrandt4.   

Abstract

Axon injury in response to trauma or disease stimulates a self-destruction program that promotes the localized clearance of damaged axon segments. Sterile alpha and Toll/interleukin receptor (TIR) motif-containing protein 1 (SARM1) is an evolutionarily conserved executioner of this degeneration cascade, also known as Wallerian degeneration; however, the mechanism of SARM1-dependent neuronal destruction is still obscure. SARM1 possesses a TIR domain that is necessary for SARM1 activity. In other proteins, dimerized TIR domains serve as scaffolds for innate immune signaling. In contrast, dimerization of the SARM1 TIR domain promotes consumption of the essential metabolite NAD+ and induces neuronal destruction. This activity is unique to the SARM1 TIR domain, yet the structural elements that enable this activity are unknown. In this study, we identify fundamental properties of the SARM1 TIR domain that promote NAD+ loss and axon degeneration. Dimerization of the TIR domain from the Caenorhabditis elegans SARM1 ortholog TIR-1 leads to NAD+ loss and neuronal death, indicating these activities are an evolutionarily conserved feature of SARM1 function. Detailed analysis of sequence homology identifies canonical TIR motifs as well as a SARM1-specific (SS) loop that are required for NAD+ loss and axon degeneration. Furthermore, we identify a residue in the SARM1 BB loop that is dispensable for TIR activity yet required for injury-induced activation of full-length SARM1, suggesting that SARM1 function requires multidomain interactions. Indeed, we identify a physical interaction between the autoinhibitory N terminus and the TIR domain of SARM1, revealing a previously unrecognized direct connection between these domains that we propose mediates autoinhibition and activation upon injury.

Entities:  

Keywords:  NAD; SARM; axon degeneration; cell death; sarmoptosis

Mesh:

Substances:

Year:  2016        PMID: 27671644      PMCID: PMC5068253          DOI: 10.1073/pnas.1601506113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  TIR domain-containing adaptor SARM is a late addition to the ongoing microbe-host dialog.

Authors:  Qing Zhang; Christian M Zmasek; Xiaohui Cai; Adam Godzik
Journal:  Dev Comp Immunol       Date:  2010-11-24       Impact factor: 3.636

Review 2.  Axon Self-Destruction: New Links among SARM1, MAPKs, and NAD+ Metabolism.

Authors:  Josiah Gerdts; Daniel W Summers; Jeffrey Milbrandt; Aaron DiAntonio
Journal:  Neuron       Date:  2016-02-03       Impact factor: 17.173

3.  Identification of interaction sites for dimerization and adapter recruitment in Toll/interleukin-1 receptor (TIR) domain of Toll-like receptor 4.

Authors:  Celia Bovijn; Peter Ulrichts; Anne-Sophie De Smet; Dominiek Catteeuw; Rudi Beyaert; Jan Tavernier; Frank Peelman
Journal:  J Biol Chem       Date:  2011-12-02       Impact factor: 5.157

4.  Depletion of the central metabolite NAD leads to oncosis-mediated cell death.

Authors:  Christopher Del Nagro; Yang Xiao; Linda Rangell; Mike Reichelt; Thomas O'Brien
Journal:  J Biol Chem       Date:  2014-10-29       Impact factor: 5.157

5.  Structural and functional analysis of a plant resistance protein TIR domain reveals interfaces for self-association, signaling, and autoregulation.

Authors:  Maud Bernoux; Thomas Ve; Simon Williams; Christopher Warren; Danny Hatters; Eugene Valkov; Xiaoxiao Zhang; Jeffrey G Ellis; Bostjan Kobe; Peter N Dodds
Journal:  Cell Host Microbe       Date:  2011-03-17       Impact factor: 21.023

6.  Structural basis for signal transduction by the Toll/interleukin-1 receptor domains.

Authors:  Y Xu; X Tao; B Shen; T Horng; R Medzhitov; J L Manley; L Tong
Journal:  Nature       Date:  2000-11-02       Impact factor: 49.962

7.  A Toll-interleukin 1 repeat protein at the synapse specifies asymmetric odorant receptor expression via ASK1 MAPKKK signaling.

Authors:  Chiou-Fen Chuang; Cornelia I Bargmann
Journal:  Genes Dev       Date:  2004-12-29       Impact factor: 11.361

8.  Peptide-mediated interference of TIR domain dimerization in MyD88 inhibits interleukin-1-dependent activation of NF-{kappa}B.

Authors:  Maria Loiarro; Claudio Sette; Grazia Gallo; Andrea Ciacci; Nicola Fantò; Domenico Mastroianni; Paolo Carminati; Vito Ruggiero
Journal:  J Biol Chem       Date:  2005-03-08       Impact factor: 5.157

9.  Mitochondrial dysfunction induces Sarm1-dependent cell death in sensory neurons.

Authors:  Daniel W Summers; Aaron DiAntonio; Jeffrey Milbrandt
Journal:  J Neurosci       Date:  2014-07-09       Impact factor: 6.167

10.  T-cell death following immune activation is mediated by mitochondria-localized SARM.

Authors:  P Panneerselvam; L P Singh; V Selvarajan; W J Chng; S B Ng; N S Tan; B Ho; J Chen; J L Ding
Journal:  Cell Death Differ       Date:  2012-11-23       Impact factor: 15.828

View more
  48 in total

Review 1.  Emergence of SARM1 as a Potential Therapeutic Target for Wallerian-type Diseases.

Authors:  Heather S Loring; Paul R Thompson
Journal:  Cell Chem Biol       Date:  2019-11-21       Impact factor: 8.116

2.  The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD+ Cleavage Activity that Promotes Pathological Axonal Degeneration.

Authors:  Kow Essuman; Daniel W Summers; Yo Sasaki; Xianrong Mao; Aaron DiAntonio; Jeffrey Milbrandt
Journal:  Neuron       Date:  2017-03-22       Impact factor: 17.173

3.  The axon degeneration gene SARM1 is evolutionarily distinct from other TIR domain-containing proteins.

Authors:  Harsha Malapati; Spencer M Millen; William J Buchser
Journal:  Mol Genet Genomics       Date:  2017-04-26       Impact factor: 3.291

Review 4.  Roles of palmitoylation in axon growth, degeneration and regeneration.

Authors:  Sabrina M Holland; Gareth M Thomas
Journal:  J Neurosci Res       Date:  2017-02-02       Impact factor: 4.164

Review 5.  Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence.

Authors:  Luis Rajman; Karolina Chwalek; David A Sinclair
Journal:  Cell Metab       Date:  2018-03-06       Impact factor: 27.287

6.  Identification of the first noncompetitive SARM1 inhibitors.

Authors:  Heather S Loring; Sangram S Parelkar; Santanu Mondal; Paul R Thompson
Journal:  Bioorg Med Chem       Date:  2020-07-17       Impact factor: 3.641

7.  Death Receptor 6 Promotes Wallerian Degeneration in Peripheral Axons.

Authors:  Kanchana K Gamage; Irene Cheng; Rachel E Park; Mardeen S Karim; Kazusa Edamura; Christopher Hughes; Anthony J Spano; Alev Erisir; Christopher D Deppmann
Journal:  Curr Biol       Date:  2017-03-09       Impact factor: 10.834

Review 8.  Mechanisms of injury-induced axon degeneration.

Authors:  Chen Ding; Marc Hammarlund
Journal:  Curr Opin Neurobiol       Date:  2019-05-06       Impact factor: 6.627

Review 9.  NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential.

Authors:  Na Xie; Lu Zhang; Wei Gao; Canhua Huang; Peter Ernst Huber; Xiaobo Zhou; Changlong Li; Guobo Shen; Bingwen Zou
Journal:  Signal Transduct Target Ther       Date:  2020-10-07

10.  c-Jun N-terminal kinase (JNK)-mediated phosphorylation of SARM1 regulates NAD+ cleavage activity to inhibit mitochondrial respiration.

Authors:  Hitoshi Murata; Cho Cho Khine; Akane Nishikawa; Ken-Ichi Yamamoto; Rie Kinoshita; Masakiyo Sakaguchi
Journal:  J Biol Chem       Date:  2018-10-17       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.